Results 221 to 230 of about 583,846 (360)

Correction to "Synthesis of a New Purine Analogue Class with Antifungal Activity and Improved Potency against Fungal IP_3-4K". [PDF]

ACS Infect Dis
Desmarini D, Truong D, Sethiya P, Liu G, Bowring B, Jessen H, Dinh H, Cain AK, Thompson PE, Djordjevic JT.   +9 more
europepmc   +1 more source

DDEL-25. Increasing the Potency of Chemotherapy Particles for GBM Treatment by Mediating Trafficking to Autolysosomes [PDF]

Alexis Cooper, Abigail Rohey, Benjamin Umlauf   +2 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Editorial: Emerging technologies for viability enumeration of live microorganisms

Frontiers in Microbiology
Hanan R. Shehata, Marco Pane, Elna M. Buys, Binu Koshy, Christina S. Vegge, Jean L. Schoeni   +5 more
doaj   +1 more source

Anticholinergics, executive function, and cognitive/behavioral changes in Down syndrome. [PDF]

Alzheimers Dement
Lee NR, McQuaid GA, Jiddou H, McNulty J, Grosman HE, Tucker KT, O'Brien M, Wallace GL.   +7 more
europepmc   +1 more source

Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency

Clinical Gastroenterology and Hepatology, 2017
D. Graham, Aylin Tansel
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. [PDF]

J Med Chem
Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, Deryabina M, Demmer O, Skarbaliene J, Hamprecht DW, Rist W, Baader-Pagler T, Grube A, Heim-Riether A, Giehm L.   +14 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Cone snail venom-inspired somatostatin receptor 4 (SSTR₄) agonists as new drug leads for peripheral pain. [PDF]

Sci Rep
Bjørn-Yoshimoto WE, Ramiro IBL, Koch TL, Engholm E, Yeung HY, Sørensen KK, Goddard CM, Jensen KL, Smith NA, Martin LF, Smith BJ, Madsen KL, Jensen KJ, Patwardhan A, Safavi-Hemami H.   +14 more
europepmc   +1 more source